|
|
|
| Prokaryotic Expression and Purification of Bioactive Human CXCL4 |
| ZHOU Liang1, YE Hao2, ZHOU Li1, GUAN Wen1, LI Jing-jing2, GAO Jin2, HAN Wei2, YU Yan1 |
1. Shanghai Jiao Tong University, Shanghai Key Laboratory of Veterinary Biological Technology School of Agriculture and Biology, Shanghai 200240, China;
2. Shanghai Jiao Tong University, Laboratory of Regenerationmic, School of Pharmacy, Shanghai 200240, China |
|
|
|
Abstract CXCL4,Platelet factor 4 (PF4), belongs to the subfamily of CXC chemokines, which is reported to be involved in numerous biological process by acting on a broad spectrum of different cell types. Here, the study aimed to express and purify recombinant human CXCL4 protein using E. coli expression system and affinity chromotography methods. The results demonstrated a simple and efficient strategy for the production and purification of recombinant human CXCL4 (rhCXCL4) with over 95% purity by gel electrophoresis have been developed. Its biological activity was confirmed in the proliferation-inhibition assay using a tumor cell line, ACHN cells. The rhCXCL4 will facilitate the structural and functional analysis of human CXCL4. The production strategy of rhCXCL4 should have important reference values for the expression and purification of other chemokines.
|
|
Received: 20 August 2015
Published: 11 January 2016
|
|
|
|
|
| [1] Deutsch E, Johnson S A,Seegers W H. Differentiation of certain platelet factors related to blood coagulation. Circulation Research,1955, 3(1):110-115.
[2] Modi W S,Chen Z Q. Localization of the human CXC chemokine subfamily on the long arm of chromosome 4 using radiation hybrids. Genomics,1998, 47(1):136-139.
[3] Deuel T F, Keim P S, Farmer M, et al. Amino acid sequence of human platelet factor 4. Proceedings of the National Academy of Sciences of the United States of America,1977, 74(16):2256-2258.
[4] Gao J, Wu M, Gao J, et al. Generation and characterization of a new monoclonal antibody against CXCL4. Monoclonal Antibodies in Immunodiagnosis and Immunotherapy,2015, 34(2):110-115.
[5] Vandercappellen J, Van Damme J,Struyf S. The role of the CXC chemokines platelet factor-4 (CXCL4/PF-4) and its variant (CXCL4L1/PF-4var) in inflammation, angiogenesis and cancer. Cytokine & Growth Factor Reviews,2011, 22(1):1-18.
[6] Kaplan K L, Broekman M J, Chernoff A, et al. Platelet alpha-granule proteins: studies on release and subcellular localization. Blood,1979, 53(4):604-618.
[7] Pilatova K, Greplova K, Demlova R, et al. Role of platelet chemokines, PF-4 and CTAP-III, in cancer biology. Journal of Hematology & Oncology,2013, 6(42):1-8.
[8] Lasagni L, Grepin R, Mazzinghi B, et al. PF-4/CXCL4 and CXCL4L1 exhibit distinct subcellular localization and a differentially regulated mechanism of secretion. Blood,2007, 109(10):4127-4134.
[9] de Jong E K, de Haas A H, Brouwer N, et al. Expression of CXCL4 in microglia in vitro and in vivo and its possible signaling through CXCR3. Journal of Neurochemistry,2008, 105(5):1726-1736.
[10] Schaffner A, Rhyn P, Schoedon G, et al. Regulated expression of platelet factor 4 in human monocytes--role of PARs as a quantitatively important monocyte activation pathway. Journal of Leukocyte Biology,2005, 78(1):202-209.
[11] Wang Z,Huang H. Platelet factor-4 (CXCL4/PF-4): an angiostatic chemokine for cancer therapy. Cancer Letters,2013, 331(2):147-153.
[12] Fricke I, Mitchell D, Petersen F, et al. Platelet factor 4 in conjunction with IL-4 directs differentiation of human monocytes into specialized antigen-presenting cells. FASEB Journal: Official Publication of the Federation of American Societies for Experimental Biology,2004, 18(13):1588-1590.
[13] Kolber D L, Knisely T L,Maione T E. Inhibition of development of murine melanoma lung metastases by systemic administration of recombinant platelet factor 4. Journal of the National Cancer Institute,1995, 87(4):304-309.
[14] Sorensen H P,Mortensen K K. Advanced genetic strategies for recombinant protein expression in Escherichia coli. Journal of Biotechnology,2005,115(2):113-128.
[15] Chen R. Bacterial expression systems for recombinant protein production: E. coli and beyond. Biotechnology Advances,2012, 30(5):1102-1107.
[16] Rosano G L,Ceccarelli E A. Recombinant protein expression in Escherichia coli: advances and challenges. Frontiers in Microbiology,2014,5(172):1-17.
[17] Choi J H,Lee S Y. Secretory and extracellular production of recombinant proteins using Escherichia coli. Applied Microbiology and Biotechnology,2004, 64(5):625-635.
[18] Haitjema C H, Boock J T, Natarajan A, et al. Universal genetic assay for engineering extracellular protein expression. ACS Synthetic Biology,2014,3(2):74-82.
[19] Su L, Xu C, Woodard R W, et al. A novel strategy for enhancing extracellular secretion of recombinant proteins in Escherichia coli. Applied Microbiology and Biotechnology,2013,97(15):6705-6713.
[20] Leone S, Sannino F, Tutino M L, et al. Acetate: friend or foe? Efficient production of a sweet protein in Escherichia coli BL21 using acetate as a carbon source. Microbial Cell Factories,2015,14(106):1-10.
[21] Lasagni L, Francalanci M, Annunziato F, et al. An alternatively spliced variant of CXCR3 mediates the inhibition of endothelial cell growth induced by IP-10, Mig, and I-TAC, and acts as functional receptor for platelet factor 4. The Journal of Experimental Medicine,2003,197(11):1537-1549.
[22] Romagnani P, Annunziato F, Lasagni L, et al. Cell cycle-dependent expression of CXC chemokine receptor 3 by endothelial cells mediates angiostatic activity. The Journal of Clinical Investigation,2001,107(1):53-63.
[23] Mueller A, Meiser A, McDonagh E M, et al. CXCL4-induced migration of activated T lymphocytes is mediated by the chemokine receptor CXCR3. Journal of Leukocyte Biology,2008,83(4):875-882.
[24] Bodnar R J,Wells A. Differential regulation of pericyte function by the CXC receptor 3. Wound Repair and Regeneration,2015,23(6):785-796. |
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
| |
Shared |
|
|
|
|
| |
Discussed |
|
|
|
|
